Carta vs Forge For A Life Sciences Consulting Firm

If the firm holds government research contracts, works with export-controlled technology, or has any connection to critical technology sectors, a change of ownership involving a foreign person or entity can trigger CFIUS or export-control review, even for a relatively small equity stake. Screen every prospective buyer, internal or external, against this question before pricing anything. Existing partners are rarely foreign persons in a way that raises this issue, which is one more reason an internal Carta-run buyback tends to be the lower-friction starting point for firms with any government contract exposure.

Consulting firms in this space often hold client-confidential research findings and their own proprietary methodologies, both of which an outside institutional buyer's standard diligence process would want visibility into. Weigh that exposure honestly; a firm with genuinely sensitive IP has a real reason to prefer Carta's internal process even before considering foreign-ownership questions. Ask each senior scientist whose work would appear in a diligence packet how comfortable they are with that exposure, since their answer often surfaces sensitivity concerns leadership had not fully considered.

Life sciences consulting can carry lumpier cash flow than a subscription business, tied to project timelines and grant cycles, so model internal funding capacity against a conservative view of near-term project revenue rather than a strong-quarter number. A firm with genuinely limited internal funding may need Forge regardless of the IP and foreign-ownership concerns, which then makes the vetting questions above even more important to resolve carefully. Build the model around a slow-quarter scenario specifically, since a firm that only tests its best quarter will consistently overestimate what it can safely fund.

If outside capital is genuinely needed, work with counsel to screen prospective institutional buyers for foreign-ownership questions before opening any diligence access, and consider whether a narrower, non-controlling structure reduces both the review burden and the IP exposure. This adds real time to a Forge-sourced process here compared with a typical SaaS company, so build that into the timeline from the outset rather than discovering it mid-transaction.

A firm with sensitive IP, potential foreign-ownership review exposure and adequate internal cash should lean firmly toward Carta. A firm that genuinely needs outside capital should still start with the buyer-screening question before anything else, since discovering a review requirement after diligence has already begun costs far more time than screening for it up front.

Rather than treating buyer screening as a one-off exercise built fresh for each liquidity event, create a standing checklist the firm can reuse: which contracts and technology categories trigger foreign-ownership review, which questions to ask a prospective buyer up front, and which counsel to engage for the assessment. A firm that runs this screen consistently across every transaction, not just the ones that feel obviously sensitive, avoids the situation where a seemingly routine buyer turns out to raise a real review question discovered too late.

A reusable screening checklist should cover these items:

• Which government contracts and technology categories trigger foreign-ownership or export-control review for your firm.
• The questions to put to every prospective buyer, internal or external, before anything is priced.
• Which counsel to engage for the assessment, and at what point in the process to bring them in.
• How much client-confidential research and proprietary methodology would end up in an outside buyer's diligence data room.
• Whether a narrower, non-controlling structure would reduce both the review burden and the IP exposure.

A ten-person consultancy with one government research contract and no plans for outside capital still benefits from doing this screening exercise once, even if the answer is simply confirming no current exposure exists, so that the firm has a documented baseline to update as its client base and contract mix evolve. Waiting until a liquidity event is already underway to ask these questions for the first time is the most common way firms in this space end up surprised by a review requirement.

For the common case, a founding scientist or senior consultant nearing retirement, no active government contracts with foreign-ownership implications, and adequate firm reserves, Carta's internally funded process is straightforward and avoids raising any of the screening questions above in the first place. Most firms in this space that have never touched a government contract or held genuinely sensitive client IP can treat this closer to a routine professional-services buyout than a specialized transaction, and should not let the more exotic scenarios above make the process feel more intimidating than it needs to be.

Weigh a wider marketplace option here.